Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2010

View Archived Issues

Pritumumab is active in patients with brain cancer

GlycoVaxyn reports phase I data on Shigella dysenteriae vaccine

IPI-926 is well tolerated and active in patients with solid tumors

GAA peptide-loaded DC1-based vaccine shows promise in recurrent malignant glioma

French scientists claim new inhibitors of cell division protein kinases

Prosidion describes new GPR119 receptor agonists

Continuous exenatide delivery with ITCA-650 shows promise in phase II diabetes trial

Preclinical and phase I data presented on Algipharma's OligoG

Takeda and Envoy Therapeutics collaborate on schizophrenia research

UCB and Synosia Therapeutics enter into strategic neurology alliance

Novartis renews agreement with WHO to provide free leprosy drugs

Bazedoxifene launched in Japan and Spain for postmenopausal osteoporosis

Almirall presents pharmacological profile of LAS-189913, a new candidate therapeutic for MS

Bristol-Myers Squibb acquires ZymoGenetics

First patient with spinal cord injury is treated in phase I trial of GRNOPC1

FDA funds phase I trial of genetically reprogrammed HSV in childhood cancer

Phase II trial studies sildenafil for heart failure in Duchenne's muscular dystrophy

Pfizer to acquire King Pharmaceuticals and expand pain product portfolio

FDA warns of increased risk of thigh bone fracture with bisphosphonates use

Merck & Co. claims new diacylglycerol O-acyltransferase 1 inhibitors

Olatec Industries patents agents with anti-inflammatory and analgesic potential

New deuterated alpha-(N-sulfonamido)acetamide beta-APP42 production inhibitors claimed

ERYtech and Genzyme to conduct feasibility studies with new therapeutic enzyme formulation

Shire acquires 99.21% of Movetis shares, proceeding with squeeze-out of remaining shares

Twice-daily tramadol/acetaminophen approved in eight European countries

Innate Therapeutics begins phase II trial of MIS-416 in progressive MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...